125 related articles for article (PubMed ID: 37951052)
1. Detection of circulating normal and tumor plasma cells in newly diagnosed patients of multiple myeloma and their associations with clinical and laboratory parameters.
Gupta L; Suku P; Dash A; Bose P; Sharma P; Mallik N; Sreedharanunni S; Varma N; Jandial A; Malhotra P; Sachdeva MUS
Curr Probl Cancer; 2024 Feb; 48():101025. PubMed ID: 37951052
[TBL] [Abstract][Full Text] [Related]
2. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
[TBL] [Abstract][Full Text] [Related]
3. Circulating Plasma Cells at the Time of Collection of Autologous PBSC for Transplant in Multiple Myeloma Patients is a Negative Prognostic Factor Even in the Age of Post-Transplant Maintenance Therapy.
Cowan AJ; Stevenson PA; Libby EN; Becker PS; Coffey DG; Green DJ; Hyun TS; Fromm JR; Gopal AK; Holmberg LA
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1386-1391. PubMed ID: 29481870
[TBL] [Abstract][Full Text] [Related]
4. Multiple myeloma patients with low proportion of circulating plasma cells had similar survival with primary plasma cell leukemia patients.
An G; Qin X; Acharya C; Xu Y; Deng S; Shi L; Zang M; Sui W; Yi S; Li Z; Hao M; Feng X; Jin F; Zou D; Qi J; Zhao Y; Tai YT; Wang J; Qiu L
Ann Hematol; 2015 Feb; 94(2):257-64. PubMed ID: 25231928
[TBL] [Abstract][Full Text] [Related]
5. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
[TBL] [Abstract][Full Text] [Related]
6. Circulating plasma cells in newly diagnosed symptomatic multiple myeloma as a possible prognostic marker for patients with standard-risk cytogenetics.
Vagnoni D; Travaglini F; Pezzoni V; Ruggieri M; Bigazzi C; Dalsass A; Mestichelli F; Troiani E; Falcioni S; Mazzotta S; Natale A; Angelini M; Ferretti S; Angelini S; Galieni P
Br J Haematol; 2015 Aug; 170(4):523-31. PubMed ID: 26010293
[TBL] [Abstract][Full Text] [Related]
7. Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma.
Gonsalves WI; Rajkumar SV; Gupta V; Morice WG; Timm MM; Singh PP; Dispenzieri A; Buadi FK; Lacy MQ; Kapoor P; Gertz MA; Kumar SK
Leukemia; 2014 Oct; 28(10):2060-5. PubMed ID: 24618735
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis.
Sidana S; Tandon N; Dispenzieri A; Gertz MA; Dingli D; Jevremovic D; Morice WG; Kapoor P; Kourelis TV; Lacy MQ; Hayman SR; Buadi FK; Leung N; Go RS; Lin Y; Russell SJ; Lust JA; Zeldenrust SR; Warsame R; Hwa YL; Hobbs M; Fonder A; Kyle RA; Rajkumar SV; Kumar SK; Gonsalves WI
Leukemia; 2018 Jun; 32(6):1421-1426. PubMed ID: 29483709
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis.
Liu X; Wu F; Ye W; Deng J; Zhang M; Zhang C; Yu Q; Cao L; Gan S; Ma J
BMJ Open; 2024 Jan; 14(1):e071548. PubMed ID: 38216195
[TBL] [Abstract][Full Text] [Related]
10. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
Lemoli RM; Cavo M; Fortuna A
J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
[TBL] [Abstract][Full Text] [Related]
11. Quantification of circulating clonal plasma cells by multiparametric flow cytometry as a prognostic marker in patients with newly diagnosed multiple myeloma.
Sathya P; Kayal S; Srinivas BH; Hamide A; Kar R
Int J Lab Hematol; 2023 Dec; 45(6):917-926. PubMed ID: 37632156
[TBL] [Abstract][Full Text] [Related]
12. Risk stratification in myeloma by detection of circulating plasma cells prior to autologous stem cell transplantation in the novel agent era.
Chakraborty R; Muchtar E; Kumar SK; Jevremovic D; Buadi FK; Dingli D; Dispenzieri A; Hayman SR; Hogan WJ; Kapoor P; Lacy MQ; Leung N; Gertz MA
Blood Cancer J; 2016 Dec; 6(12):e512. PubMed ID: 27983726
[TBL] [Abstract][Full Text] [Related]
13. Circulating plasma cells as a predictive biomarker in Multiple myeloma: an updated systematic review and meta-analysis.
Li Q; Ai L; Zuo L; Li J; Zhao F; Xu A; Zhang B; Cai L; Hu Y; Sun C
Ann Med; 2024 Dec; 56(1):2338604. PubMed ID: 38599340
[TBL] [Abstract][Full Text] [Related]
14. Quantification of clonal circulating plasma cells in relapsed multiple myeloma.
Gonsalves WI; Morice WG; Rajkumar V; Gupta V; Timm MM; Dispenzieri A; Buadi FK; Lacy MQ; Singh PP; Kapoor P; Gertz MA; Kumar SK
Br J Haematol; 2014 Nov; 167(4):500-5. PubMed ID: 25113422
[TBL] [Abstract][Full Text] [Related]
15. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients: positive selection and transplantation of enriched CD34+ cells to remove circulating tumor cells.
Lemoli RM; Fortuna A; Motta MR; Rizzi S; Giudice V; Nannetti A; Martinelli G; Cavo M; Amabile M; Mangianti S; Fogli M; Conte R; Tura S
Blood; 1996 Feb; 87(4):1625-34. PubMed ID: 8608257
[TBL] [Abstract][Full Text] [Related]
16. Enhancing the R-ISS classification of newly diagnosed multiple myeloma by quantifying circulating clonal plasma cells.
Gonsalves WI; Jevremovic D; Nandakumar B; Dispenzieri A; Buadi FK; Dingli D; Lacy MQ; Hayman SR; Kapoor P; Leung N; Fonder A; Hobbs M; Hwa YL; Muchtar E; Warsame R; Kourelis TV; Russell S; Lust JA; Lin Y; Go RS; Siddiqui MA; Kyle RA; Gertz MA; Rajkumar SV; Kumar SK
Am J Hematol; 2020 Mar; 95(3):310-315. PubMed ID: 31867775
[TBL] [Abstract][Full Text] [Related]
17. Quantification of circulating clonal plasma cells via multiparametric flow cytometry identifies patients with smoldering multiple myeloma at high risk of progression.
Gonsalves WI; Rajkumar SV; Dispenzieri A; Dingli D; Timm MM; Morice WG; Lacy MQ; Buadi FK; Go RS; Leung N; Kapoor P; Hayman SR; Lust JA; Russell SJ; Zeldenrust SR; Hwa L; Kourelis TV; Kyle RA; Gertz MA; Kumar SK
Leukemia; 2017 Jan; 31(1):130-135. PubMed ID: 27457702
[TBL] [Abstract][Full Text] [Related]
18. Is multidrug resistance (P-glycoprotein) an intrinsic characteristic of plasma cells in patients with monoclonal gammopathy of undetermined significance, plasmacytoma, multiple myeloma and amyloidosis?
Mongkonsritragoon W; Kimlinger T; Ahmann G; Greipp PR
Leuk Lymphoma; 1998 May; 29(5-6):577-84. PubMed ID: 9643571
[TBL] [Abstract][Full Text] [Related]
19. [Detection of circulating and bone marrow myeloma cells in patients with multiple myeloma and its clinical significance].
Jiang YQ; Li JY; Wu YJ; Yang H; Shen YF; Chen LJ; Xu W; Qian SX; Wu HX; Lu H; Shen RL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Oct; 14(5):908-12. PubMed ID: 17096887
[TBL] [Abstract][Full Text] [Related]
20. Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma.
Flores-Montero J; de Tute R; Paiva B; Perez JJ; Böttcher S; Wind H; Sanoja L; Puig N; Lecrevisse Q; Vidriales MB; van Dongen JJ; Orfao A
Cytometry B Clin Cytom; 2016 Jan; 90(1):61-72. PubMed ID: 26100534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]